Physician profile
Brian Thomas Bennett
NPI 1780657270
$5,417.52
in general payments reported to CMS, 2019-2025
43 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $163 · 2021: $690 · 2022: $880 · 2023: $1,155 · 2024: $872 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $754.49 | 2019-2025 | |
| Glaxosmithkline, LLC. | $680.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $439.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $321.36 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $321.22 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $262.45 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $259.12 | 2021-2025 | Farxiga |
| Lilly USA, LLC | $251.64 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.65 | 2021-2025 | Jardiance, Spiriva Respimat |
| Abbvie INC. | $144.60 | 2022-2024 | Vraylar, Ubrelvy |
| Dexcom, INC. | $119.38 | 2021-2024 | Dexcom G6 Transmitter |
| Abiomed | $114.55 | 2022-2023 | Impella |
| Kowa Pharmaceuticals America, INC. | $113.30 | 2019-2025 | Zoryve |
| Astellas Pharma US INC | $109.66 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $104.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.